When trametinib was compared with chemotherapy (DTIC or paclitaxel) in 322 patients with BRAF-mutated melanoma, median PFS and 6 month OS rates were greater in the trametinib group, at 4.8 months and 81%, versus 1.5 months and 67% in the chemotherapy group [31]. This evidence concerns the gene BRAF and melanoma.